TrialNature communications2026

Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.

Qihua Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.